Lymphoma | Topics

FDA Places Partial Clinical Hold on TakeAim Lymphoma Trial Assessing Emavusertib in Lymphoma
April 19, 2022

The phase 1/2 TakeAim Lymphoma trial examining emavusertib for patients with B-cell malignancies has received a partial clinical hold pending review by the FDA.

Current Treatments in Marginal Zone Lymphoma
April 18, 2022

This review provides an updated analysis of the literature and discusses the authors' approach to the diagnosis and treatment of patients with marginal zone lymphoma.

Topline Results Reported in Phase 1/2 Trial of Epcoritamab in R/R LBCL
April 17, 2022

Investigators reported topline findings from the phase 1/2 EPCORE NHL-1 trial assessing epcoritamab in patients with relapsed/refractory large B-cell lymphoma.

Frederick Locke, MD, Talks Unmet Needs Reduced by Axi-Cel Use in LBCL
April 16, 2022

Frederick Lock, MD, spoke about how axicabtagene ciloleucel has improved survival in patients with large B-cell lymphoma.

Ibrutinib Plus Venetoclax at a Fixed Duration Yields Positive PFS in CLL/SLL
April 12, 2022

Ibrutinib plus venetoclax given at a fixed duration yielded favorable progression-free survival in patients with previously untreated, high-risk chronic lymphocytic leukemia and small lymphocytic lymphoma.

European Commission Approves Liso-Cel for Select Relapsed/Refractory Large B-Cell Lymphoma
April 11, 2022

The European Commission approved lisocabtagene maraleucel for the treatment of certain patients with relapsed/refractory large B-cell lymphoma.

Analysis Reveals Associations Between T-Cell Attributes of Axi-cel and Outcomes in LBCL
April 10, 2022

Biomarker analysis and studies of pharmacokinetics, pharmacodynamics, and T-cell composition show certain T-cell characteristics are linked with outcomes and toxicity with axicabtagene ciloleucel in large B-cell lymphoma.

AMF13 Plus Natural Killer Cells Produced Encouraging Early Responses in Heavily Pretreated Lymphoma
April 10, 2022

Investigators of a phase 1/2 trial observed positive response outcomes with expanded natural killer cells plus AMF13 in patients with heavily pretreated lymphoma.

Frederick Locke, MD, Discusses Recent Approval of Axi-Cel in Relapsed/Refractory LBCL
April 08, 2022

Frederick Lock, MD, spoke about the approval of axicabtagene ciloleucel and how it’s beneficial for patients with large B-cell lymphoma who were treated with frontline chemoimmunotherapy.

FDA Grants Approval to Axi-Cel for Adults With LBCL Following First-Line Chemoimmunotherapy
April 01, 2022

Based on results of the ZUMA-7 trial, the FDA approved axicabtagene ciloleucel for the treatment of certain patients with large B-cell lymphoma who received chemoimmunotherapy in the frontline setting.